Clinical Trial Update: Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of ASP2215 in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

This update reports the completion of a Phase 1 dose-escalation study of ASP2215 (gilteritinib) in Japanese patients with Relapsed or Refractory Acute Myeloid L…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• ASP2215

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Acute Myeloid Leukemia (AML) | Phase 1 | Status: COMPLETED